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Abstract
There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the
potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The
development of oral medications is a key objective of the Consortium for Parasitic Drug Development (CPDD). In this study,
we investigated the safety, pharmacokinetics, and efficacy of a new orally administered CPDD diamidine prodrug, 2,5-bis[5-
(N-methoxyamidino)-2-pyridyl]furan (DB868; CPD-007-10), in the vervet monkey model of first stage HAT. DB868 was well
tolerated at a dose up to 30 mg/kg/day for 10 days, a cumulative dose of 300 mg/kg. Mean plasma levels of biomarkers
indicative of liver injury (alanine aminotransferase, aspartate aminotransferase) were not significantly altered by drug
administration. In addition, no kidney-mediated alterations in creatinine and urea concentrations were detected.
Pharmacokinetic analysis of plasma confirmed that DB868 was orally available and was converted to the active compound
DB829 in both uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 days post-infection.
In the infected monkeys, DB829 attained a median Cmax (dosing regimen) that was 12-fold (3 mg/kg/day for 7 days), 15-fold
(10 mg/kg/day for 7 days), and 31-fold (20 mg/kg/day for 5 days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense
STIB900. DB868 cured all infected monkeys, even at the lowest dose tested. In conclusion, oral DB868 cured monkeys with
first stage HAT at a cumulative dose 14-fold lower than the maximum tolerated dose and should be considered a lead
preclinical candidate in efforts to develop a safe, short course (5–7 days), oral regimen for first stage HAT.
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Introduction
Human African trypanosomiasis (HAT, sleeping sickness) is
caused by two trypanosome species that are transmitted through
the bite of blood-sucking tsetse flies (Glossina spp). Trypanosoma
brucei (T. b.) gambiense is endemic to West and Central Africa,
while T. b. rhodesiense is endemic to East and Southern Africa [1].
The disease is focal in distribution and is marked by wide
temporal and spatial variations in incidence and prevalence [2–
4]. HAT is characterised by two clinical stages. During the first
(early, haemolymphatic) stage, trypanosomes proliferate at the
site of the fly bite, travel to local lymph nodes and bloodstream,
and progressively invade other tissues [5]. Approximately 3–4
weeks post-infection with T. b. rhodesiense, or months to years with
T. b. gambiense, trypanosomes invade the central nervous system
(CNS), initiating the second (late, meningo-encephalitic) stage of
HAT [5]. Second stage HAT is marked by neurological and
endocrine disorders. If patients are not treated, they lapse into
coma and die [6].
HAT chemotherapy is stage specific. Only two drugs have been
approved for the treatment of first stage HAT, pentamidine and
suramin. Pentamidine, a diamidine first used clinically in 1941, is
used to treat first stage T. b. gambiense infections. Suramin, a
naphthylurea first introduced for clinical use in 1921, is effective
against both trypanosome species but is mainly used against first
stage T. b. rhodesiense HAT [7,8]. Pentamidine is associated with
hypoglycaemia, pain at the injection site, diarrhoea, nausea and
vomiting, while suramin is associated with hypersensitivity
reactions, albuminuria, haematuria and peripheral neuropathy
[7]. In addition, these drugs must be administered via intramus-
cular injection or intravenous infusion in well-equipped hospitals,
which are not readily available or accessible in rural areas where
HAT typically occurs. To overcome these limitations, two orally
active compounds, fexinidazole and the oxaborole SCYX-7158,
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have recently entered clinical development to treat both stages of
the disease [9]. In addition, efforts by the Consortium for Parasitic
Drug Development (CPDD) to address these limitations have
resulted in the synthesis of a collection of diamidines with
promising pharmacologic properties [10,11].
One of the new aza diamidines, 2,5-bis(5-amidino-2-pyridyl)-
furan (DB829; Figure 1), exhibited an IC50 of 14 nmol/L against
T. b. rhodesiense STIB900 in vitro [12]. In addition, it was shown to
be 100% curative in both the acute (T. b. rhodesiense STIB900) and
chronic CNS (T. b. brucei GVR35) mouse models of HAT after
intraperitoneal administration [12]. However, the dicationic
nature of DB829 and other diamidines (e.g., pentamidine and
furamidine) contributes to poor permeation through biologic
membranes and in turn, poor systemic exposure after oral
administration [13]. As such, a prodrug of DB829 was designed,
2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868; Figure 1),
by masking the cationic functionalities of the active compound
with methoxy groups [14]. Oral administration of DB868 was
100% curative in both the acute and chronic CNS mouse models
of HAT [12]. Based on these desirable properties, DB868
progressed into our vervet monkey model to assess its potential
as a new lead compound for oral treatment of first stage HAT.
The purpose of this study was to evaluate DB868 metabolism in
monkey liver microsomes, safety in uninfected monkeys, pharma-
cokinetics in both uninfected and infected monkeys, and efficacy in
infected monkeys.
Materials and Methods
Ethics
This study was conducted in accordance with experimental
guidelines and procedures (Ref: C/TR/4/325/116) approved by
the Institutional Animal Care and Use Committee (IACUC) at the
Kenya Agricultural Research Institute’s Trypanosomiasis Re-
search Centre (KARI-TRC). These IACUC regulations con-
formed to national guidelines provided by the Kenya Veterinary
Association.
Trypanocidal Test and Comparator Drugs
The test drug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan diac-
etate (DB868; CPD-007-10; Lot #2-JXS-28; Base MW = 366.37;
FW = 564.37), was supplied by the University of North Carolina-led
CPDD as a yellow powder stored in opaque, water tight bottles. In the
laboratory, the drug-containing vials were wrapped in aluminium foil
as further protection from light and stored at room temperature. The
drug was dissolved fresh daily in distilled de-ionised water
(pH 4.560.2) at concentrations permitting administration of 2 mL/
kg body weight per oral administration. For example, a 15 mg/mL
dose solution was prepared for animals receiving a dose of 30 mg/kg
and a 10 mg/mL dose solution for a dose of 20 mg/kg. Pentamidine
isethionate, supplied by the World Health Organization (WHO), was
used as the comparator drug. Pentamidine was dissolved in sterile
distilled water and administered intramuscularly at 0.5 mL/kg body
weight.
Experimental Animals
Eighteen vervet monkeys, also known as African green monkeys
or Chlorocebus (Cercopithecus) aethiops, weighing from 2.0 to 4.5 kg,
were acquired from the Institute of Primate Research in Kenya.
To ensure animal welfare and ameliorate suffering, upon arrival at
KARI-TRC, the monkeys were subjected to standard quarantine
procedures, including screening for zoonotic and non-zoonotic
diseases/infections and treatment for both endo- and ectopara-
sites, for a minimum of 90 days prior to study commencement as
previously described [15,16]. They became accustomed to staying
in individual squeeze-back stainless steel cages during this time.
The monkeys were maintained on a diet of fresh fruits and
vegetables (bananas, tomatoes, carrots and green maize) and
commercial monkey cubes (Unga Feeds, Nakuru, Kenya) fed twice
daily, and were given water ad libitum. The commercial monkey
cubes were manufactured to have the following nutrient compo-
sition: crude protein, 19.4% (w/w); crude fiber, 5.6% (w/w); ether
extracts that include fats and lipids, 4.2% (w/w); and nitrogen-free
extracts, 66.5% (w/w).
Metabolism of DB868 in Vervet Monkey Liver
Microsomes
DB868 metabolism was studied in male vervet monkey liver
microsomes (custom-prepared by XenoTech, LLC, Lenexa, KS, USA)
by adapting a previously published method [17]. Briefly, incubation
Figure 1. Structures of the prodrug (DB868) and active compound (DB829).
doi:10.1371/journal.pntd.0002230.g001
Author Summary
Development of orally administered medicines for human
African trypanosomiasis (HAT) would potentially reduce
the need for patient hospitalization, thus lowering
healthcare costs. In this study, we investigated the
potential of a novel diamidine prodrug, DB868 (CPD-007-
10), as an oral treatment for first stage HAT. When
administered to uninfected monkeys by oral gavage,
DB868 was well tolerated up to a maximum dose of
30 mg/kg/day for 10 days (cumulative dose
[CD] = 300 mg/kg). DB868 was absorbed into the systemic
circulation and was converted to the active compound
DB829 in concentrations that were potentially therapeutic
for blood trypanosomes. Subsequently, DB868 was evalu-
ated for efficacy in the first stage vervet monkey model of
HAT in which treatment was initiated at 7 days post-
infection with T. b. rhodesiense KETRI 2537. All infected
monkeys were cured, even at the lowest of the three dose
regimens tested: 3 mg/kg/day for 7 days (CD = 21 mg/kg),
10 mg/kg/day for 7 days (CD = 70 mg/kg) and 20 mg/kg/
day for 5 days (CD = 100 mg/kg). DB868 conversion to
DB829 was comparable between uninfected and infected
monkeys. In view of its favourable safety and oral efficacy
profile, we conclude that DB868 is a suitable candidate for
development as a new treatment for first stage HAT.
Pharmacology of Oral DB868 in a HAT Monkey Model
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mixtures contained 10 mM DB868, 0.5 mg/mL monkey liver
microsomes, and 3.3 mM MgCl2 in 100 mM phosphate buffer
(pH 7.4). Reactions were initiated by the addition of NADPH (1 mM
final concentration). Control incubations were carried out without
NADPH, DB868, or liver microsomes. Aliquots (100 mL) of the
reaction mixtures were removed at 0, 5, 10, 15, 30, 60 and 120 min
and mixed with 100 mL of ice-cold acetonitrile. After centrifugation to
pellet precipitated proteins, the supernatants were analyzed by HPLC/
UV and fluorescence using the method previously described for
pafuramidine (DB289) and furamidine (DB75) [18]. Metabolite
identification was performed by comparing retention times to those
of synthetic standards for M1 (DB1679), M2 (DB840), M3 (DB1712),
and DB829. DB868 and its metabolites were quantified using a
calibration curve (0.1–10 mM) generated using synthetic standards.
Safety and Pharmacokinetics in Uninfected Monkeys
Eight uninfected vervet monkeys, divided into two dose-groups
of four monkeys (two females and two males) each, were used.
Baseline weight and clinical and haematological data were
collected over a 14-day period, after which the monkeys were
orally administered DB868 at 10 mg/kg/day (group 1) or 30 mg/
kg/day (group 2) for 10 days (Table 1). Care was taken to avoid
spillage and to minimise the time between drug preparation and
dosing. Drug administration utilized a dose volume of 2 mL/kg
body weight. The animals were monitored for indicators of overt
toxicity, including changes in feed intake, weight, demeanour,
posture and stool composition and consistency. Feed intake was
assessed by scoring the proportion of the daily ration consumed by
each monkey on a scale of 1 (full ration eaten), L, K, J, and 0
(no feed eaten) as previously described [15]. To increase chances
of detecting potential drug-related gastrointestinal toxicity, stool
samples were collected and examined visually and by faecal occult
blood tests conducted according to the modified guaiac method
[19]. Post-last drug dose (LDD) monitoring extended to a
minimum of 60 days.
During pre- and post-dose monitoring, monkeys were anaesthetized
by intramuscular injection of ketamine HCl (10–15 mg/kg) to facilitate
physical examination, body weight measurements, and sample
collection. Blood was collected from the femoral vein via inguinal
venipuncture as described previously [16] and divided into aliquots:
1 mL blood into EDTA-containing tubes (1.5 mg EDTA/mL blood)
for full haemogram determination and 2 mL blood into EDTA-
containing tubes for plasma separation. Plasma was separated using a
cool spin centrifuge (1500 rpm for 10 min at 4uC). The harvested
plasma was divided into aliquots for clinical chemistry determinations
(500 mL), prodrug (DB868) and active compound (DB829) concentra-
tion measurement (150 mL), and preservation as a stock sample
(approximately 250 mL). All plasma aliquots were frozen at 220uC
before analysis.
Efficacy and Pharmacokinetics in Infected Monkeys
The efficacy of DB868 administered orally at 20 mg/kg/day for
5 days was compared to that of pentamidine administered
intramuscularly at 4 mg/kg/day for 7 days. To obtain an
indication of dose response, DB868 also was evaluated at 10 and
3 mg/kg/day, administered orally for 7 days. The 10 and 3 mg/
kg dose regimens were evaluated at a time when a regulator-
imposed freeze on the acquisition of non-human primates was in
force, hence only 2 animals were available per dose group. In each
experiment, a 14-day baseline data collection period was observed,
after which the monkeys were infected by intravenous injection of
104 T. b. rhodesiense KETRI 2537 trypanosomes diluted from the
infected blood of immuno-suppressed donor Swiss white mice
[16]. Post-infection monitoring for the development of parasitae-
mia was initiated at three days post-infection (DPI) while treatment
began 7 DPI, subsequent to confirmation of first stage HAT
(defined as trypanosomes detectable in blood and not cerebrospi-
nal fluid [CSF], and CSF white cell counts less than 5 cells/mm3)
[16]. Ear-prick blood samples to determine parasitaemia were
collected prior to daily drug administration. Clinical and
parasitological cure was evaluated for at least six months as
previously described [16]. In our studies with the related prodrug
DB844, plasma samples collected out to 28 days post-LDD (6 mg/
kg) were insufficient to recover a robust estimate of the elimination
half-life of the active compound DB820 [20]; therefore, in the
current study, plasma samples were collected for at least 60 days
post-LDD for pharmacokinetic analysis. Haematology samples
were analysed using an AC3diffT Coulter Counter (Miami, FL,
USA). Clinical chemistry determinations were performed using a
Humalyzer analyser system. Plasma was analyzed for prodrug and
Table 1. Pharmacokinetics of DB868 and DB829 in uninfected vervet monkeys after the final (10th) oral dose of DB868.
Compound Outcome Units Oral DB868
10 mg/kg610 days 30 mg/kg610 days
Monkey ID 643 659 675 677 546 567 668 679
DB868 C4 h nmol/L 50 130 39 250 1600 280 320 330
C24 h nmol/L BLQ BLQ 6 BLQ 38 47 35 66
AUClast nmol/LNday NC NC NC NC 530 210 170 190
AUC0-‘ nmol/LNday NC NC NC NC 540 260 180 200
t1/2 day NC NC NC NC 1 1 1.3 0.4
DB829 C4 h nmol/L 240 160 180 170 290 300 270 440
C24 h nmol/L 140 260 120 170 210 280 340 360
AUClast nmol/LNday 3000 2800 2100 2100 5700 4600 7100 4700
AUC0-‘ nmol/LNday 3700 3700 4100 2400 7000 6200 12100 5600
t1/2 day 30 30 55 18 24 29 47 22
Key: C4 h, concentration at 4 h; C24 h, concentration at 24 h; AUClast, area under the curve from time zero to the last measurable concentration; AUC0-‘, area under the
curve from time zero to infinite time; tK, terminal elimination half-life; BLQ, below limit of quantitation; NC, not calculable.
doi:10.1371/journal.pntd.0002230.t001
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active compound concentrations using high performance liquid
chromatography-tandem mass spectrometry (HPLC-MS/MS) as
described below.
Handling of Moribund Infected Monkeys
Monkeys that were deemed as treatment failures/relapses or
developed severe adverse clinical signs as defined in the protocol
(e.g., inability or reluctance to perch, less than J of normal daily
feed intake for 2–3 consecutive days) were immediately withdrawn
from the study and humanely euthanized for post-mortem
examination. These monkeys were euthanized by intravenous
administration of 20% (w/v) pentobarbitone sodium solution
(150 mg/kg body weight; Euthatal; Rhône-Mérieux, United
Kingdom).
Figure 2. Metabolism of the prodrug DB868 in monkey liver microsomes. HPLC/UV chromatograms (A) and concentration-time profiles (B)
of the prodrug DB868, intermediate metabolites, and active compound (DB829) following incubation of DB868 with male vervet monkey liver
microsomes were shown. Incubation mixtures (1 mL at pH 7.4) contained 10 mM DB868, 0.5 mg/mL monkey liver microsomes, and 1 mM NADPH.
Aliquots were removed at 1, 5, 15, 30 and 120 min, and analyzed for DB868, three intermediate metabolites (M1, M2, M3), and DB829 by HPLC/UV.
Metabolite M4 was not quantified due to the lack of a synthetic standard. Symbols and error bars represent means and SDs of triplicate incubations.
doi:10.1371/journal.pntd.0002230.g002
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HPLC-MS/MS Quantification of DB868 and DB829 in
Monkey Plasma
Monkey plasma samples were processed for quantification of
DB868 and DB829 using previously described methods [21,22]
with modifications made to the transition and mass spectrometer
parameters. DB868-d6P (DB868 with deuterated pyridyl rings;
30 nM) and DB829-d6 (DB829 with deuterated pyridyl rings;
30 nM) were used as internal standards and were supplied by the
CPDD. Prodrug and active compound were separated on an
Aquasil C18 HPLC column (5062.1 mm, 5 mm; Thermo Fisher
Scientific, Waltham, MA, USA) and quantified using an Applied
Biosystems API 4000 triple quadrupole mass spectrometer
equipped with a Turbo V source and electrospray probe (Foster
City, CA, USA). The following transitions (in positive ion mode)
were used in multiple reaction monitoring scans: 367.1R320.2
(DB868), 373.7R323.2 (DB868-d6P), 307.1R290.1 (DB829), and
313.2R296.2 (DB829-d6). Calibration standards and quality
controls were prepared in blank monkey plasma to mimic the
matrix of the unknown test samples. Analyte concentrations were
reported only for those samples that were between the standards
and controls that had an accuracy and precision within
100%620%. If samples were below this range, data are reported
as below the limit of quantification. Data below the limit of
quantification were not used for the pharmacokinetic analysis.
Data Analysis
Data were analysed statistically using StatView for Windows
Version 5.0.1 (SAS Institute Inc., Cary, NC, USA) as previously
published [20]. Repeated measures ANOVA, with Fisher’s PLSD
post hoc test, was used to test the effects of trypanosomal infection,
as well as DB868, on haematological and clinical chemistry
parameters in comparison with respective baseline values
(a= 0.05). Confidence intervals (95%) were derived to further test
the significance of observed findings. The clinical data arising from
the efficacy study are presented descriptively since the group sizes
were too small for statistical analysis. Pharmacokinetic outcomes
were determined with standard non-compartmental methods
using Phoenix WinNonlin (version 6.2; Pharsight, Mountain
View, CA, USA).
Results
Conversion of Prodrug to Active Compound in Monkey
Liver Microsomes
The prodrug DB868 was metabolized in male vervet monkey
liver microsomes to M1 (DB1679), M2 (DB840), M3 (DB1712),
M4, and the active compound DB829 (Figure 2). These
metabolites were similar to those observed when DB868 was
incubated with human liver microsomes [23]. Detection of these
metabolites indicated that, like pafuramidine (DB289) and DB844,
DB868 undergoes sequential O-demethylation and N-dehydrox-
ylation reactions to form the active compound DB829 in monkey
liver microsomes. M2 (DB840), a bis-amidoxime metabolite, had
the highest concentration at the end of the 120-min incubation.
DB829 was at the limit of detection in UV mode; however,
formation was confirmed by subsequent parallel fluorescence and
mass spectrometric detection (data not shown).
Overt Toxicity and Haematology in Uninfected Monkeys
Uninfected monkeys administered DB868 orally at 10 mg/kg/
day for 10 days (n = 4) did not exhibit any adverse clinical signs
throughout the study. In addition, two of the four monkeys in the
30 mg/kg/day group did not display overt toxicity. The remain-
ing two monkeys exhibited mild signs of toxicity, including excess
mucous in the stool (monkey 567) and transient inappetance 1–2
days post-LDD (monkeys 567 and 546). In general, stool texture
and consistency was unchanged and faecal occult blood tests
revealed nothing significant in any study subject, suggesting that
no notable gastrointestinal toxicity occurred. The mean body
weight of monkeys in the 30 mg/kg group exhibited minimal
variation (Figure 3), with a maximum decline of 6.5% from
baseline (3.1 kg60.3). A maximum decline of 6.2% from baseline
(3.2 kg60.5) was observed in the 10 mg/kg group (data not
shown). Overall, the two oral DB868 dose regimens were well
tolerated.
Haematological parameters of the two treatment groups did not
vary significantly from baseline throughout the study. For the
30 mg/kg group, the baseline mean red blood cell (RBC) and
platelet counts (6 SE) were 5.5 (60.1)6106 and 3.7 (60.2)6105
cells/mL of blood, respectively, and showed little change through-
out the study (p = 0.10 and 0.06, respectively; Figure 3). Similarly,
no significant variations were seen in the RBC or platelet counts
for the 10 mg/kg group (data not shown). The mean white blood
cell (WBC) count exhibited a minor transient increase post-LDD
(1.5-fold over the baseline count (6 SE) of 4.8 (60.5)6103 cells/
mL of blood; p = 0.05; Figure 3), which returned to baseline after
24 h. A comparable trend was seen in the WBC count of the
10 mg/kg group (data not shown), as well as in a separate monkey
that was not administered drug or vehicle but had blood sampled
at the same time as monkeys in the current experiment, suggesting
that the change in the WBC count was not drug-related.
Clinical Chemistry
Plasma biomarkers of liver injury, alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and total and direct
bilirubin, were monitored in uninfected monkeys prior to
(baseline), during, and following completion of the 10-day
DB868 dosing regimens. At the two baseline time points (216
and 210 days post-LDD), mean (6 SE) ALT levels were 14.6
(63.1) and 11.1 (62.3) IU/L, respectively, for the 10 mg/kg
group and 27.3 (613.0) and 16.0 (67.2) IU/L for the 30 mg/kg
group. During and following the completion of dosing, mean ALT
levels varied considerably in the 10 mg/kg group (Figure 4A). The
highest post-treatment mean ALT values observed were 2.8-fold
(31.3/11.1) greater than the second baseline sample for the
10 mg/kg group and 1.3-fold (20.5/16.0) for the 30 mg/kg group.
Neither variation was statistically significant (p = 0.71, 10 mg/kg
group; p = 0.37, 30 mg/kg group). Mean AST and total and direct
bilirubin levels also exhibited variability prior to, during, and
following dosing (Figure 4, B and C) but overall, were not
statistically different from baseline values (p.0.05).
Two biomarkers of kidney injury, creatinine and urea, were also
evaluated in plasma samples. Mean (6 SE) creatinine concentra-
tions at the two baseline time points were 63.6 (64.0) and 54.1
(65.5) mmol/L, respectively, for the 10 mg/kg group and 61.5
(614.5) and 57.3 (66.0) mmol/L for the 30 mg/kg group. Post-
dosing variations were minimal (Figure 5A) and not statistically
significant (p.0.05). However, mean urea levels exhibited a
transient increase following the completion of each dosing regimen
(Figure 5B; Figure S1). Plasma urea peaked 1–2 days post-LDD
and was 2.1- and 2.7-fold greater than baseline for the 10 mg/kg
and 30 mg/kg groups, respectively (both p,0.05). To determine
whether increases in plasma urea levels were due to kidney
dysfunction, the blood urea nitrogen (BUN):creatinine ratio was
calculated for the 1–2 days post-LDD period. The peak mean urea
concentration for the 10 mg/kg group was 12.8 mmol/L, which is
equivalent to 35.9 mg/dL of BUN. The mean creatinine
Pharmacology of Oral DB868 in a HAT Monkey Model
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concentration was 72.3 mmol/L (equivalent to 0.8 mg/dL).
Therefore, the BUN:creatinine ratio was 45:1 (35.9:0.8). The
BUN:creatinine ratio for the 30 mg/kg group was higher at 48:1.
Pharmacokinetics in Uninfected Monkeys
Following oral administration of the prodrug DB868 to
uninfected monkeys, DB868 was detected in plasma at 4 h post-
LDD (Figure 6; Table 1). DB868 concentrations declined to below
the limit of detection (BLD) within 1–2 days post-LDD for the
30 mg/kg group and in less than 1 day post-LDD for the 10 mg/
kg group (data not shown). Accurate recovery of pharmacokinetic
outcomes for DB868 was precluded for the 10 mg/kg dose group
(Table 1). Greater inter-individual variability was observed for the
4 h post-LDD concentration (C4 h) of DB868 than for DB829
(Table 1). The geometric mean DB868 C4 h for the 30 mg/kg
group (466 nmol/L) was 5.2-fold greater than that for the 10 mg/
kg group (89 nmol/L). The geometric mean DB829 C4 h for the
30 mg/kg group (320 nmol/L) was 1.6-fold greater than that for
the 10 mg/kg group (185 nmol/L). The geometric mean AUClast
and AUC0-‘ for DB829 in the 30 mg/kg group were 2.2-fold
greater than that in the 10 mg/kg group. The geometric mean
terminal elimination half-life for DB829 was comparable between
the two dose groups (29 and 31 days, respectively).
Disease Progression and Efficacy
Following inoculation, the median (range) prepatent period of
T. b. rhodesiense infection in the monkeys was 4.5 (3–6) days
(Table 2; Figure 7). The bloodstream form of T. b. rhodesiense
KETRI 2537 trypanosomes multiplied rapidly, reaching a peak
mean count of 1.16107 trypanosomes/mL blood; in some
monkeys, the count peaked as high as 1.36108 trypanosomes/
mL (antilog 8.1; Table 2). Classical signs of T. b. rhodesiense
infection were observed, including rough hair coat, dullness,
marked loss of appetite, and marginal declines in body weight (4%
of pre-infection weight) and RBC count (7% of pre-infection
value). Rectal body temperature increased from a pre-infection
mean (6 SE) of 38.3 (60.2)uC to a high of 38.7 (60.2)uC at 7 DPI;
however, the increase was not statistically significant (p = 0.06).
Trypanosomes were not detected, nor were white cell counts
elevated in the CSF (data not shown), confirming that the monkeys
were in the first stage of disease when treatment was initiated at 7
DPI. The prodrug DB868 was administered orally to three groups
of monkeys: 20 mg/kg/day for 5 days (n = 3), 10 mg/kg/day for 7
days (n = 2), or 3 mg/kg/day for 7 days (n = 2). A fourth group of
monkeys (n = 3) was treated intramuscularly with the comparator
drug, pentamidine, at 4 mg/kg/day for 7 days (Table 2). Both oral
DB868 and intramuscular pentamidine demonstrated efficacy
against first stage infection as discussed below. Trypanosome-
associated waves of parasitaemaia were not observed (Figure 7),
likely because all infections were treated during the first wave of
parasitaemia.
DB868 at 20 mg/kg/day65 Days. Three monkeys, 585,
658 and 686, were treated orally with DB868 at 20 mg/kg/day
for 5 days. In all monkeys, trypanosomes were undetectable in
Figure 3. Changes in body weight and haematological parameters in uninfected vervet monkeys administered DB868. The monkeys
(n = 4) were administered DB868 orally at 30 mg/kg/day for 10 days, day 29 to day 0 post-last drug dose. Symbols and error bars represent means
and SEs, respectively, of body weight, red blood cell count (RBC), white blood cell count (WBC), and platelet count (PLT).
doi:10.1371/journal.pntd.0002230.g003
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blood by direct microscopy or the haematocrit centrifugation
technique [24] by the 4th day of drug administration. The
monkeys remained trypanosome-free in body fluids (blood and
CSF) for the remaining monitoring period (Table 2). Monkeys
686 and 585 were withdrawn from the study and humanely
euthanized 4 and 145 days post-LDD, respectively (Table 2), due
to the continued deterioration of their health. Trypanosome
recrudescence had not occurred in either monkey. Upon post-
mortem examination, monkey 686 had peritoneal abscesses while
monkey 585 had pneumonia, suggesting that their decline in
health was unrelated to drug therapy. The remaining monkey
(monkey 658) was monitored over 525 days post-LDD without
any parasitological or clinical evidence of relapse and was
declared cured.
Figure 4. Changes in plasma biomarkers of liver injury in uninfected vervet monkeys administered DB868. DB868 was administered
orally at 10 mg/kg/day (n = 4) or 30 mg/kg/day (n = 4) for 10 days, day 29 to day 0 post-last drug dose. Symbols and error bars represent means and
SEs, respectively, of (A) alanine aminotransferase (ALT), (B) aspartate aminotransferase (AST), and (C) total and direct bilirubin (T. BIL and D. BIL,
respectively) levels.
doi:10.1371/journal.pntd.0002230.g004
Pharmacology of Oral DB868 in a HAT Monkey Model
PLOS Neglected Tropical Diseases | www.plosntds.org 7 June 2013 | Volume 7 | Issue 6 | e2230
DB868 at 10 mg/kg/day67 Days. Upon treatment with
10 mg/kg/day DB868 orally for 7 days, monkey 691 was parasito-
logically negative on the 6th day of treatment while monkey 675
became consistently negative 7 days post-LDD. The two monkeys
remained negative throughout the remaining post-treatment monitor-
ing period (Table 2). Monkey 675, however, was only monitored up to
114 days post-LDD, at which time it was withdrawn from the study
and euthanized due to clinical deterioration. Post-mortem examination
indicated pneumonia to be the cause of declining health. Monkey 691
was monitored over 525 days post-LDD without a relapse and was
declared cured.
DB868 at 3 mg/kg/day67 Days. Two monkeys, 638 and
643, were treated orally with DB868 at 3 mg/kg/day for 7 days.
Monkey 638 was parasitologically negative on the 6th day of
dosing, while monkey 643 was 3 days post-LDD. Both monkeys
remained trypanosome-free throughout the extended monitoring
period of greater than 500 days and were declared cured
(Table 2).
Pentamidine at 4 mg/kg/day67 Days. Three monkeys,
541, 651 and 672, were administered pentamidine intramuscularly
at 4 mg/kg/day for 7 days. Trypanosomes were not detected in
monkeys 541 and 651 immediately prior to the third dose.
However, trypanosomes were observed intermittently in monkey
672, including 3 days post-LDD when its clinical condition
deteriorated, necessitating euthanasia. Monkeys 541 and 651 were
monitored over 600 days post-LDD without any evidence of
relapse and were declared cured (Table 2).
Pharmacokinetics of DB868 and DB829 in Infected
Monkeys
The prodrug DB868 was detected in the plasma of all monkeys
with first stage HAT, regardless of the dosing regimen, at 0.04
Figure 5. Changes in plasma biomarkers of kidney injury in uninfected vervet monkeys administered DB868. DB868 was administered
orally at 10 mg/kg/day (n = 4) or 30 mg/kg/day (n = 4) for 10 days, day 29 to day 0 post-last drug dose. Symbols and error bars represent means and
SEs, respectively, of (A) creatinine and (B) urea.
doi:10.1371/journal.pntd.0002230.g005
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days (1 h) post-LDD (data not shown). The Tmax varied between
individuals, with the majority (4/6 monkeys) occurring at 0.04
days (1 h) post-LDD. DB868 concentrations declined rapidly.
Only one monkey (monkey 675; 10 mg/kg/day for 7 days) had
detectable levels at 8 h post-LDD, precluding accurate recovery of
pharmacokinetic outcomes for DB868. The median Cmax for
DB829 for the 20 and 10 mg/kg groups (435 and 205 nmol/L,
respectively) were 2.6- and 1.2-fold higher, respectively, than that
for the 3 mg/kg group (170 nmol/L) (Figure 8; Table 3). The
median Tmax for the 20 and 3 mg/kg groups were similar (4 h),
whereas that for the 10 mg/kg group was longer (1 day). The
median Tmax for DB829 in each dose group was longer than that
for DB868. The mean AUClast for DB829 in the 20 and 10 mg/kg
groups was 10- and 7-fold greater, respectively, than that in the
3 mg/kg group (Table 3). Accurate AUC0-‘ and terminal
elimination half-life were only recoverable for the 20 mg/kg
group and one monkey in the 10 mg/kg group, precluding
between-dose comparisons. The median AUC0-‘ and terminal
elimination half-life for the 20 mg/kg group were twice those of
the one (monkey 691) in the 10 mg/kg group (Table 3).
Discussion
Consistent with observations involving human liver microsomes
[23], vervet monkey liver microsomes metabolized the prodrug
DB868 to four intermediate metabolites and the active compound
DB829. Similar metabolic pathways have been reported for the
related prodrugs pafuramidine and DB844 in rat, monkey and
human liver microsomes [20,25–27], demonstrating that these
alkoxy-type diamidine prodrugs [28] are converted to active
compounds in different animal species. The low DB829 concen-
trations in the microsomal samples were not unexpected, as similar
results were observed with the active compound generated from
the related prodrug pafuramidine [17]. The final metabolic steps
in the formation of DB829, the N-hydroxylation of M2 and
subsequently M4, are analogous to those in the conversion of
pafuramidine to furamidine. During microsomal pafuramidine
metabolism, these steps are catalyzed by cytochrome b5/b5
reductase [29]. This enzyme is also abundant in mitochondria
and Golgi [29,30], explaining why DB868 is more efficiently
converted to DB829 in intact hepatocytes compared to the isolated
microsomal system [27,31]. Collectively, these results provided
justification for in vivo testing of the prodrug DB868 in uninfected
and infected vervet monkeys.
No significant overt toxicity was seen with up to 30 mg/kg/day
DB868 orally for 10 days (cumulative dose [CD] = 300 mg/kg) in
the vervet monkey safety study, suggesting that this dose was below
the maximum tolerated dose, but slightly above the no observed
adverse effect level (NOAEL). Pharmacokinetic analysis of plasma
from the uninfected monkeys showed that the geometric mean
C4 h of the active compound DB829 in the 30 and 10 mg/kg
groups were 23- and 13-fold greater than the IC50 (14 nmol/L)
Figure 6. Plasma concentration-time profiles of DB829 following administration of the prodrug DB868 to uninfected vervet
monkeys. DB868 was administered orally at 10 mg/kg/day (n = 4) or 30 mg/kg/day (n = 4) for 10 days, day 29 to day 0 post-last drug dose. Symbols
and error bars represent geometric means and SEs of the active compound DB829 concentrations, respectively. The inset graph shows the plasma
concentration-time profiles starting at day 0 post-last drug dose on a logarithmic scale.
doi:10.1371/journal.pntd.0002230.g006
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against T. b. rhodesiense STIB900, respectively. These results
confirmed that DB868/DB829 are available systemically following
oral administration, similar to pafuramidine/furamidine and
DB844/DB820 [20,32], prompting further evaluation in the
monkey model of first stage HAT.
Based on the above observations, DB868 efficacy was evaluated
in vervet monkeys with first stage HAT using doses below 30 mg/
kg/day in order to minimise the risk of unfavourable clinical
outcomes. Dosing durations of 5–7 days were chosen based on the
hypothesis that first stage disease can be cured using short treatment
durations. DB868, administered orally, cured all monkeys of their
experimentally introduced T. b. rhodesiense infection (Table 2). Post-
treatment monitoring must be at least 180 days in order to declare a
cure in the monkey model of first stage HAT [16]. All three DB868
dosing regimens, including the lowest evaluated (3 mg/kg/day for 7
days; CD = 21 mg/kg), effectively cleared the monkeys of their
considerably high parasitaemia, which in some cases was as high as
108 trypanosomes/mL of blood. Elimination of the pathogens
allowed the monkeys to return to their clinical and haematological
baselines within one month post-LDD (data not shown), similar to
Figure 7. Changes in mean parasitaemia values of vervet monkeys treated with DB868. Starting at 7 days post-infection with T. b.
rhodesiense KETRI 2537, monkeys confirmed to have first stage HAT were treated with either DB868 orally or pentamidine intramuscularly. DB868 at
20 mg/kg/day for 5 days (n = 2); DB868 at 10 mg/kg/day for 7 days (n = 2); DB868 at 3 mg/kg/day for 7 days (n = 2); pentamidine at 4 mg/kg/day for 7
days (n = 3). Symbols and error bars represent means and interindividual differences (range), respectively.
doi:10.1371/journal.pntd.0002230.g007
Table 2. Efficacy of oral DB868 and intramuscular pentamidine against first stage T. b. rhodesiense infection in vervet monkeys.
Parameter/Outcome Oral DB868 Intramuscular Pentamidine
20 mg/kg65 days
10 mg/kg67
days
3 mg/kg67
days 4 mg/kg67 days
Monkey ID 585 658 686 675 691 638 643 651 541 672
Prepatent period (days post-infection) 5 5 4 5 3 4 4 4 5 6
Peak parasitaemia (Log10 P) 7.2 6.9 6.0 7.8 7.8 8.1 8.1 5.4 7.8 5.4
Trypanosomes blood/CSF at EoT Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos
Provisional efficacy at 100 days post-treatment Cured Cured WD Cured Cured Cured Cured Cured Cured WD
Duration of post-treatment monitoring 145 620 4 114 525 525 525 620 620 2
Final efficacy assesment WD Cured WD WD Cured Cured Cured Cured Cured Not cured
Key: P = parasitaemia; EoT = end of treatment; Neg = negative; Pos = positive; WD = withdrawn.
doi:10.1371/journal.pntd.0002230.t002
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what was observed in pafuramidine and DB844 efficacy studies
conducted in this monkey model [16,20]. These results highlight the
ability of diamidines to eliminate injurious trypanosomes, allowing
the body to repair/heal itself. Furthermore, oral DB868 appears to
be superior to oral pafuramidine in this first stage HAT monkey
model, as a higher dose of pafuramidine than DB868 was required
to achieve complete cure (10 mg/kg for 5 days vs. 3 mg/kg for 7
days, respectively) [16]. The longer dose regimen for DB868
compared to pafuramidine is consistent with the in vitro observation
that DB829 required longer exposure periods than furamidine to kill
T. b. brucei s427 trypanosomes [33]. For example, a 24-h exposure to
DB829 (2.7 mM) was required, whereas a 1-h exposure to
furamidine (3.2 mM) was required to kill these trypanosomes in
culture.
Figure 8. Plasma concentration-time profiles of DB829 following administration of the prodrug DB868 to infected vervet monkeys.
The monkeys confirmed to have first stage HAT were administered DB868 orally, beginning at 7 days post-infection, at 20 mg/kg/day for 5 days,
10 mg/kg/day for 7 days, or 3 mg/kg/day for 7 days. The inset graph shows the extended DB829 profiles up to 150 days post-last DB868 dose. *
denotes the time (4 days post-last drug dose) that monkey 686 was euthanized due to clinical morbidity (peritoneal abscesses).
doi:10.1371/journal.pntd.0002230.g008
Table 3. Pharmacokinetics of DB829 in vervet monkeys with first stage HAT after the final oral dose of DB868.
Outcome Units Oral DB868
20 mg/kg65 days 10 mg/kg67 days 3 mg/kg67 days
Monkey ID 585 658 675 691 638 643
Cmax nmol/L 370 500 210 200 110 230
Tmax day 0.17 0.17 0.17 2.0 0.04 0.33
AUClast{ nmol/LNday 7300 4100 4000 3500 160 950
AUC0-‘ nmol/LNday 10000 5300 NC 3900 NC NC
t1/2 day 85 24 NC 25 NC NC
Key: Cmax, maximum concentration; Tmax, time to reach maximum concentration; AUClast, area under the curve from time zero to the last measurable concentration;
AUC0-‘, area under the curve from time zero to infinite time; tK, terminal elimination half-life; NC, not calculable due to .30% extrapolation of the AUC0-‘;
{ = last measurable concentration varied between monkeys (2–133 days).
doi:10.1371/journal.pntd.0002230.t003
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Based on a mg dose basis, DB868 has a larger therapeutic
window than pafuramidine in vervet monkeys. No notable
drug-induced overt toxicity was observed in either uninfected
or infected monkeys administered DB868, except for mild
excess mucous in the stool (n = 1) and transient inappetance
(n = 2) in the group receiving 30 mg/kg/day for 10 days. In
comparison, similar mild adverse events were observed when
pafuramidine was administered at 10 mg/kg/day for 10 days
to vervet monkeys (unpublished data; JK Thuita). DB868, at
all doses tested, did not cause significant elevations in plasma
biomarkers of liver (ALT, AST, total and direct bilirubin;
Figure 4) and kidney (creatinine; Figure 5) injury. These results
contrasted with those of pafuramidine, which caused transient
liver injury during an extended phase I clinical trial in humans
[11]. In addition, only a slight increase in ALT (less than 2-
fold) was observed in female Sprague-Dawley rats adminis-
tered DB868 orally (25 mg/kg/day for 3 weeks) compared to
untreated rats, whereas an 18-fold increase was observed in
rats administered pafuramidine (12 mg/kg/day for 4 weeks)
[34]. In the current study, plasma urea concentrations, and
therefore BUN levels, were transiently increased (2–3-fold;
Figure 5B) shortly (1–2 days) after the last drug dose. However,
the BUN:creatinine ratio was above the critical 20:1 ratio,
suggesting that the elevations were likely due to pre-renal
causes such as dehydration. Direct comparison of plasma liver
and kidney injury biomarkers between DB868 and pafurami-
dine in vervet monkeys are not possible due to insufficient data
on pafuramidine. Nevertheless, the safety profile of DB868 is
improved over that of the prodrug DB844, which caused
significant liver injury when administered to monkeys at doses
above 10 mg/kg/day [20], necessitating withdrawal of DB844
from further development.
As discussed above, our study has demonstrated that oral
DB868 has excellent efficacy and an improved therapeutic
window in the first stage HAT monkey model, making it a
promising lead candidate for further preclinical development.
However, based on the previous lessons learned from the
development of pafuramidine [11], several issues warrant mention.
First, the kidney safety liability of DB868 needs to be further
examined using more predictive models and biomarkers. Pafur-
amidine development was terminated due to an unexpected severe
kidney injury that occurred in five patients (,6%), a liability not
predicted by traditional preclinical safety testing in rodents [11].
Recently, Harrill et al. [21] showed, using a mouse diversity panel
comprised of 34 genetically diverse inbred mouse strains, marked
elevations of urinary kidney injury molecule-1 (KIM-1) in sensitive
mouse strains following oral administration of pafuramidine, while
classical kidney injury biomarkers, BUN and serum creatinine,
remained unchanged. Hence, it may be prudent to screen DB868
for kidney injury liability using the sensitive mouse strains therein
identified and KIM-1. Encouraging results from Sprague Dawley
rats administered pafuramidine or DB868 orally (12 mg/kg/
day628 days) showed that DB868 had no effect on KIM-1 during
the entire 4-month observation period (28 days of drug
administration and 92 days of recovery period), whereas pafur-
amidine caused a 13-fold increase in KIM-1 one week post-LDD
[34].
Second, treatment regimens should be optimized with the
pharmacokinetics taken into consideration. The active com-
pound DB829 was readily detected in the plasma following oral
administration of the prodrug DB868 (Figures 6 and 8).
Afterwards, DB829 was slowly eliminated from the blood with
a terminal elimination half-life ranging from days to nearly
three months depending on the dosing regimen (Tables 1 and 3).
This is similar to suramin [7], the only other first stage HAT
drug besides pentamidine. Plasma concentrations of DB829
remained .100 nmol/L for long periods following the last
DB868 dose, in some monkeys up to 7 days post-LDD. This
finding was comparable to that reported for DB844 [20] and
provides additional evidence that 1) prolonged treatment
durations may not be necessary, especially for first stage HAT,
and 2) daily dosing of DB868 and other diamidine prodrugs
may not be necessary. However, since trypanosomes are tissue
invasive, a follow-up pharmacokinetic study is needed to
determine if plasma active drug concentrations are predictive
of tissue concentrations.
Third, combined treatment of DB868 with a fast-acting
trypanocide may accelerate recovery, improve efficacy and clinical
outcomes, and prevent resistance. The time to clearance of
trypanosomes from peripheral blood was shorter in monkeys
treated with pentamidine intramuscularly (2 days after the 1st
4 mg/kg dose) than with oral DB868 (2–14 days after the 1st dose
depending on the dose; Figure 7). It took longer for the lower
DB868 dose regimen groups (3 and 10 mg/kg) to clear parasites
from the blood than the 30 mg/kg group (6–14 days vs. 2–5 days
after the 1st drug dose; Figure 7). The difference in parasite
clearance between pentamidine and DB868 (or the active
compound DB829) is consistent with observations in mouse
models of HAT (Wenzler et al., Antimicrob Agents Chemother. under
review). However, the slower parasite clearance by DB868 did not
seem to compromise efficacy in the monkey model. Nevertheless,
combining oral DB868 with another fast-acting trypanocidal
agent, such as the oral drugs currently in clinical trials, may offer
fast elimination of parasitaemia, the ease of oral pills, and a low
probability of developing resistance.
In conclusion, oral DB868 demonstrated improved efficacy and
safety profiles in the vervet monkey model of first stage HAT, in
comparison to the previous clinical candidate pafuramidine. As
such, DB868 should be considered a preclinical candidate for oral
treatment of first stage HAT, supplementing the current drug
development pipeline.
Supporting Information
Figure S1 Individual plasma urea concentration-time
profiles of uninfected vervet monkeys administered
DB868. DB868 was administered orally at 10 mg/kg/day (643,
675, 659, 677; blue symbols) or 30 mg/kg/day (567, 679, 546,
668; red symbols) for 10 days, day 29 to day 0 post-last drug dose.
(TIF)
Figure S2 Individual plasma concentration-time pro-
files of DB829 following administration of DB868 to
uninfected vervet monkeys. DB868 was administered orally
at 10 mg/kg/day (643, 675, 659, 677; blue symbols) or 30 mg/
kg/day (567, 679, 546, 668; red symbols) for 10 days day 29 to
day 0 post-last drug dose.
(TIF)
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